5-bromo-3-cyclobutoxypyrazin-2-amine | 947249-25-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 5-bromo-3-cyclobutoxypyrazin-2-amine
• 英文别名: 2-Pyrazinamine, 5-bromo-3-(cyclobutyloxy)-；5-bromo-3-cyclobutyloxypyrazin-2-amine
• CAS: 947249-25-4
• 化学式: C₈H₁₀BrN₃O
• 分子量: 244.091
• InChiKey: QWKBWXKNKGGKTQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  61
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• PI3 KINASE INHIBITORS AND METHODS OF THEIR USE
  申请人：Ni Zhi-Jie

  公开号：US20100075965A1

  公开（公告）日：2010-03-25

  Phosphatidylinositol (PI) 3 kinase inhibitor compounds, their pharmaceutically acceptable salts, and prodrugs thereof; compositions of the new compounds, either alone or in combination with at least one additional therapeutic agent, with a pharmaceutically acceptable carrier; and uses of the new compounds, either alone or in combination with at least one additional therapeutic agent, in the prophylaxis or treatment of proliferative diseases characterized by the abnormal activity of growth factors, protein serine/threonine kinases, phospholipid kinases, G-protein coupled receptors, and phosphatases.

  磷脂酰肌醇（PI）3激酶抑制剂化合物及其药学上可接受的盐和前药；新化合物的组合物，可以单独使用或与至少一种其他治疗药物结合，与药学上可接受的载体；以及新化合物的用途，可以单独使用或与至少一种其他治疗药物结合，用于预防或治疗增殖性疾病，其特征是生长因子、蛋白质丝氨酸/苏氨酸激酶、磷脂酰肌醇激酶、G蛋白偶联受体和磷酸酶的异常活性。
• PI-3 KINASE INHIBITORS AND METHODS OF THEIR USE
  申请人：NOVARTIS AG

  公开号：EP1989201A1

  公开（公告）日：2008-11-12
• [EN] PI-3 KINASE INHIBITORS AND METHODS OF THEIR USE<br/>[FR] INHIBITEURS DE KINASE PI-3 ET LEURS PROCÉDÉS D'UTILISATION
  申请人：NOVARTIS AG

  公开号：WO2007095588A1

  公开（公告）日：2007-08-23

  [EN] Phosphatidylinositol (PI) 3 kinase inhibitor compounds, their pharmaceutically acceptable salts, and prodrugs thereof; compositions of the new compounds, either alone or in combination with at least one additional therapeutic agent, with a pharmaceutically acceptable carrier; and uses of the new compounds, either alone or in combination with at least one additional therapeutic agent, in the prophylaxis or treatment of proliferative diseases characterized by the abnormal activity of growth factors, protein serine/threonine kinases, phospholipid kinases, G-protein coupled receptors, and phosphatases.
  [FR] La présente invention concerne des composés inhibiteurs de la phosphatidylinositol (PI) 3 kinase, leurs sels pharmaceutiquement acceptables, et des promédicaments de ceux-ci; des compositions des nouveaux composés, seules ou en combinaison avec au moins un autre agent thérapeutique, avec un support pharmaceutiquement acceptable; et des utilisations des nouveaux composés, seuls ou en combinaison avec au moins un autre agent thérapeutique, dans la prophylaxie ou le traitement de maladies prolifératives caractérisées par l'activité anormale de facteurs de croissance, de protéine sérine/thréonine kinases, de kinases phospholipides, de récepteurs couplés aux protéines G, et de phosphatases.
• [EN] IMIDAZO[1,2-A]PYRIDINYL DERIVATIVES AS IRAK4 INHIBITORS<br/>[FR] DÉRIVÉS D'IMIDAZO[1,2-A]PYRIDINYLE SERVANT D'INHIBITEURS D'IRAK4
  申请人：BIOGEN MA INC

  公开号：WO2020150626A1

  公开（公告）日：2020-07-23

  This invention relates to Imidazo[1,2-a]pyridinyl Derivatives of formula (I'), or pharmaceutically acceptable salts thereof, in which all of the variables are as defined in the specification, capable of modulating the activity of IRAK4. The invention further provides a method of manufacturing compounds of the invention, and methods for their therapeutic use. The invention further provides methods to their preparation, to their medical use, in particular to their use in the treatment and management of diseases or disorders including inflammatory disease, autoimmune disease, cancer, cardiovascular disease, a disease of the central nervous system, disease of the skin, an ophthalmic disease and condition, and a bone disease.